Pre-chemotherapy nutritional status and chemotherapy response: An observational study

Rao, Raghavendra; Saha, N.; Mani, V.; Ram, Amritanshu; Geetha, R.; Radheshyam, N.; Patil, Shekar; H, Shashidhara; Satheesh, T.C.; Agarwal, Vijay; Ajaikumar, B. S.

doi:10.1093/annonc/mdx388

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, prior or concomitant therapy with anti-metabolite plant alkaloids impacted on the QoL of many patients, but rescue medication was not required in the majority of cases (98.3% and 94.7%), findings similar to other published data (29,30). Aprepitant based triple therapy did not impact on the QoL of patients in contrast to solely ondansetron and dexamethasone (31) administrations, which is in agreement with the guidelines which recommend the addition of an NK-1 receptor antagonist to a 5HT 3 antagonist + corticosteroid combination to improve QoL.…”

Section: Discussionsupporting

confidence: 90%

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China

Yang

et al. 2020

Chin Clin Oncol

View full text Add to dashboard Cite

Background: The goal of this study was to evaluate aprepitant usage in the context of routine clinical practice with dose/regimens at the discretion of prescribers for chemotherapy-induced nausea and vomiting (CINV) treatments.Methods: In this single arm, multicenter prospective study 1,000 patients with solid malignancies were enrolled across 21 centers in China. The primary endpoint was the rate of adverse events (AEs), including drug related AEs and serious AEs (SAEs). Secondary efficacy endpoints included the proportion of patients achieving complete response (CR; no vomiting, no nausea, and no use of rescue medication) within 120 h Yang et al.

show abstract

Section: Discussionsupporting

confidence: 90%

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China

Yang

et al. 2020

Chin Clin Oncol

View full text Add to dashboard Cite

show abstract

“…9,10 Nutrition is an important factor in the treatment and development of cancer. 11 The observational study of Rao et al 12 showed that nutritional status before chemotherapy affected quality of life, strength, and response to chemotherapy in patients with breast malignancy.…”

Section: Introductionmentioning

confidence: 99%

BMI and TLC increase Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer

Priyono

Putra

Yasmina

et al. 2022

MKB

View full text Add to dashboard Cite

Anthracycline-based neoadjuvant chemotherapy is the recommended therapy for locally advanced breast cancer (LABC) patients. Unfortunately, no study has reported the relationship between body mass index (BMI), total lymphocyte count (TLC), and responses to this type of chemotherapy. This study aimed to determine the relationship between BMI, TLC, and response to doxorubicin/epirubicin neoadjuvant chemotherapy in LABC patients. A retrospective cohort design was applied to medical records of LABC patients undergoing neoadjuvant chemotherapy at Ulin General Hospital Banjarmasin, Indonesia, from July to December 2021. BMI and TLC data were assessed based on the values before chemotherapy, while the chemotherapy response was measured using the RECIST 1.1 criteria after 3 cycles. Multinomial logistic regression test with 95% confidence level was used to analyze these data. The results showed that as many as 71% of patients experienced a Partial Response (PR), while 5% and 23% of the patients demonstrated Stable Disease (SD) and Progressive Disease (PD), respectively. Each increase in BMI of 1 kg/m2 was significantly associated with an increase in the occurrence of PR and PD by 1.26 times and 1.29 times, respectively, when compared to the occurrence of PD. Meanwhile, an increase in TLC of 100 cells/mm3 was associated with an increase in the occurrence of PR by 6.83 times and an increase in the occurrence of SD. of 6.94 when compared to the occurrence of PD. Therefore, there is a significant relationship between BMI, TLC, and response to anthracycline-based neoadjuvant chemotherapy in LABC patients

show abstract

Pre-chemotherapy nutritional status and chemotherapy response: An observational study

Cited by 2 publications

References 0 publications

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China

BMI and TLC increase Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer

Contact Info

Product

Resources

About